Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1178605
PUBLISHER: Grand View Research | PRODUCT CODE: 1178605
Europe Branded Generics Market Size, Share & Trends Analysis Report By Drug Class (Alkylating Agents, Antimetabolites), By Application, By Route Of Administration, By Distribution Channel, By Country, And Segment Forecasts, 2023 - 2030
PUBLISHED:
PAGES: 105 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Europe Branded Generics Market Growth & Trends:
The Europe branded generics market size is expected to reach USD 61.36 billion by 2030, registering CAGR of 5.9% during the forecast period, according to a new report by Grand View Research, Inc.The prevalence of diabetes is growing rapidly in EU countries. According to WHO data for 2022, diabetes affects around 10%-20% of the population in member states of WHO European Region, which is increasing among all age groups. In 2022, a survey by WHO also reported a high prevalence of childhood obesity in Europe, stating that one in three children is overweight and obese. Thus, the growing prevalence of the disease is expected to propel Europe branded generics market.
The buyer of branded generic products include pharmacies, wholesalers, mail-order distributors, group purchasing organizations, and hospitals. Due to buyer's enhanced capacity to negotiate competitive acquisition costs and ability to maximize their profits, market is witnessing competition based simply on cost and ability to supply medicines. Individual manufacturers have minimal control above the overall drug market pricing, consequently, increasing the bargaining power of the buyers.
The flexibility, comfort, and accessibility provided by online purchases of branded generic drugs are the major factors driving the segment. In addition, the discounts provided by online pharmacies attract patients to buy drugs online, which are also projected to fuel Europe branded generics market. However, the sale of prescription medicines on online platforms is prohibited, with the sale of nonprescription-based medicines being the smallest/least, which is contributing to the low share of online pharmacies in the branded generics market.
The UK has a high penetration of generics (approximately 70.0% by volume), low entry barriers, and relatively simplified entry requirements. However, sustaining in the UK market can be difficult for the branded generics players, as there is high dominance of unbranded generics. This impedes the opportunity to differentiate by company brand or product; thus, manufacturers are mainly dependent on pricing. Moreover, physicians are not mandated to prescribe according to INN in the UK.
The government is focusing on reducing healthcare expenditure by changing pricing policies. According to a report on new pricing models for generic medicines, around 70.0% of the generic products accounted for the total medicines dispensed in Europe. The pricing of generic products is affected by the significant consolidation of current pricing policies in Europe. For example, external reference pricing, tendering, short-term cost reduction measures (such as ad hoc price cuts), and payback has resulted in a significant decline in the prices of some off-patent medicines. Such policies are anticipated to increase competition and result in price erosion. These changes in traditional policies may leverage increased negotiation for the customers and additional pricing pressure which will restrain the branded generics market.
Europe Branded Generics Market Report Highlights:
- By drug class, the others segment accounted for the largest share of the market in 2021. This can be attributed to the approval and launch of branded generics for the treatment of infectious diseases such as HIV & HPV and lifestyle diseases such as diabetes
- Based on application, oncology is expected to be the fastest growing segment during the forecast period owing to the patent expiration and approval of the branded drugs used for the treatment of various cancers
- Based on route of administration, the oral segment dominated Europe branded generics market in 2022. This can be attributed to the high preference of the patients due to its advantages, such as patient compliance, the convenience of drug administration, and non-invasiveness
- Retail pharmacy segment dominated the Europe branded generics market in 2022 and is anticipated to witness the fastest growth during the forecast period. This can be attributed to the wide availability of drugs at retail pharmacies and their ease of accessibility to the patients
- Germany dominated the market in 2022 owing to the factors such as high awareness among healthcare professionals about drugs available for the treatment and the rise in disease prevalence
Product Code: GVR-4-68040-014-9
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market segmentation
- 1.1.1 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details of Primary Research
- 1.3.6 List of Primary Sources
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.6.1 Commodity Flow Analysis
- 1.7 Market: CAGR Calculation
- 1.8 Research Assumptions
- 1.9 List of Secondary Sources
- 1.10 List of Abbreviations
- 1.11 Objectives
- 1.11.1 Objective 1
- 1.11.2 Objective 2
- 1.11.3 Objective 3
- 1.11.4 Objective 4
Chapter 2 Executive Summary
- 2.1 Market Snapshot
- 2.2 Segment Snapshot
- 2.3 Competitive Snapshot
Chapter 3 Market Variables, Trends, & Scope
- 3.1 Parent Market
- 3.1.1 Europe Branded Generics Market
- 3.2 Penetration and Growth Prospect Mapping
- 3.3 Regulatory Landscape
- 3.4 Europe Branded Generics Market Dynamics
- 3.4.1 Market Driver Analysis
- 3.4.1.1 Patent expiry of branded products
- 3.4.1.2 Increasing marketing approval and launch of branded generic products
- 3.4.1.3 Increasing disease burden and rising geriatric population
- 3.4.2 Market Restraint Analysis
- 3.4.2.1 Pricing pressure
- 3.4.3 Market Opportunity Analysis
- 3.4.3.1 Government initiatives promoting usage of generics
- 3.4.1 Market Driver Analysis
- 3.5 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
- 3.6 Porter's Five Forces Analysis
Chapter 4 Europe Branded Generics Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
- 4.1 Europe Branded Generics Market: Drug Class Movement Analysis
- 4.2 Alkylating Agents
- 4.2.1 Alkylating Agents Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 4.3 Antimetabolites
- 4.3.1 Antimetabolites Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4 Hormones
- 4.4.1 Hormones Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5 Anti-hypertensive & Lipid lowering drugs
- 4.5.1 Anti-hypertensive & lipid lowering drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.6 Anti-depressants
- 4.6.1 Anti-depressants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7 Anti-psychotics
- 4.7.1 Anti-Psychotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.8 Anti-epileptics
- 4.8.1 Anti-epileptics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.9 Others
- 4.9.1 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Europe Branded Generics Market: Segment Analysis, by Application, 2018 - 2030 (USD Million)
- 5.1 Europe Branded Generics Market: Application Movement Analysis
- 5.2 Oncology
- 5.2.1 Oncology Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 5.3 cardiovascular diseases
- 5.3.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 5.4 Neurological Diseases
- 5.4.1 Neurological Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 5.5 Acute and Chronic Pain
- 5.5.1 Acute and Chronic Pain Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 5.6 Gastrointestinal Diseases
- 5.6.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 5.7 Dermatological Diseases
- 5.7.1 Dermatological Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 5.8 Others
- 5.8.1 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Chapter 6 Europe Branded Generics Market: Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
- 6.1 Europe Branded Generics Market: Route of Administration Movement Analysis
- 6.2 Topical
- 6.2.1 Topical Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 6.3 Oral
- 6.3.1 Oral Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 6.4 Parenteral
- 6.4.1 Parenteral Market Estimates and Forecast, 2018-2030 (USD Million)
- 6.5 Others
- 6.5.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 7 Europe Branded Generics Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)
- 7.1 Europe Branded Generics Market: Distribution Channel Movement Analysis
- 7.2 Hospital Pharmacy
- 7.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
- 7.3 Retail Pharmacy
- 7.3.1 Retail Pharmacy Market Estimates and Forecast, 2018-2030 (USD Million)
- 7.4 Online Pharmacy
- 7.4.1 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 8 Europe Branded Generics Market: Regional Estimates and Trend Analysis, by Drug Class, Application, Route of Administration, & Distribution Channel
- 8.1 Europe
- 8.1.1 SWOT Analysis:
- 8.1.1.1 Europe Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.2 Germany
- 8.1.2.1 Key Country Dynamics
- 8.1.2.2 Target Disease Prevalence
- 8.1.2.3 Competitive Scenario
- 8.1.2.4 Regulatory Framework
- 8.1.2.5 Reimbursement Scenario
- 8.1.2.6 Prescription and Dispensing Scenario
- 8.1.2.7 Germany Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.3 UK
- 8.1.3.1 Key Country Dynamics
- 8.1.3.2 Target Disease Prevalence
- 8.1.3.3 Competitive Scenario
- 8.1.3.4 Regulatory Framework
- 8.1.3.5 Reimbursement Scenario
- 8.1.3.6 UK Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.4 France
- 8.1.4.1 Key Country Dynamics
- 8.1.4.2 Target Disease Prevalence
- 8.1.4.3 Competitive Scenario
- 8.1.4.4 Regulatory Framework
- 8.1.4.5 Reimbursement Scenario
- 8.1.4.6 France Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.5 Italy
- 8.1.5.1 Key Country Dynamics
- 8.1.5.2 Target Disease Prevalence
- 8.1.5.3 Competitive Scenario
- 8.1.5.4 Regulatory Framework
- 8.1.5.5 Reimbursement Scenario
- 8.1.5.6 Italy Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.6 Spain
- 8.1.6.1 Key Country Dynamics
- 8.1.6.2 Target Disease Prevalence
- 8.1.6.3 Competitive Scenario
- 8.1.6.4 Regulatory Framework
- 8.1.6.5 Reimbursement Scenario
- 8.1.6.6 Spain Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.7 Russia
- 8.1.7.1 Key Country Dynamics
- 8.1.7.2 Target Disease Prevalence
- 8.1.7.3 Competitive Scenario
- 8.1.7.4 Regulatory Framework
- 8.1.7.5 Reimbursement Scenario
- 8.1.7.6 Russia Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.8 Denmark
- 8.1.8.1 Key Country Dynamics
- 8.1.8.2 Target Disease Prevalence
- 8.1.8.3 Competitive Scenario
- 8.1.8.4 Regulatory Framework
- 8.1.8.5 Reimbursement Scenario
- 8.1.8.6 Denmark Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.9 Sweden
- 8.1.9.1 Key Country Dynamics
- 8.1.9.2 Target Disease Prevalence
- 8.1.9.3 Competitive Scenario
- 8.1.9.4 Regulatory Framework
- 8.1.9.5 Reimbursement Scenario
- 8.1.9.6 Sweden Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.10 Norway
- 8.1.10.1 Key Country Dynamics
- 8.1.10.2 Target Disease Prevalence
- 8.1.10.3 Competitive Scenario
- 8.1.10.4 Regulatory Framework
- 8.1.10.5 Reimbursement Scenario
- 8.1.10.6 Norway Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.1.11 Rest of Europe
- 8.1.1 SWOT Analysis:
Chapter 9 Europe Branded Generics Market: - Competitive Landscape
- 9.1 Recent Developments & Impact Analysis, by Key Market Participants
- 9.1.1 New Product Launch
- 9.1.2 Merger and Acquisition
- 9.1.3 Licensing Agreements
- 9.1.4 Conferences and Campaigns
- 9.2 Company Categorization
- 9.2.1 Innovators
- 9.2.2 Market Leaders
- 9.3 Vendor Landscape
- 9.3.1 List of key distributors and channel partners
- 9.3.2 Key customers
- 9.4 Public Companies
- 9.4.1 Key company market share analysis, 2021
- 9.4.2 Company market position analysis
- 9.4.3 Heat map analysis
- 9.4.4 Competitive Dashboard Analysis
- 9.4.4.1 Market Differentiators
- 9.5 Private Companies
- 9.5.1 List of key emerging companies
- 9.5.2 Regional Network Map
- 9.6 Company Profiles
- 9.6.1 Teva Pharmaceutical Industries Ltd.
- 9.6.1.1 Company overview
- 9.6.1.2 Financial performance
- 9.6.1.3 Product benchmarking
- 9.6.1.4 Strategic initiatives
- 9.6.2 LUPIN
- 9.6.2.1 Company overview
- 9.6.2.2 Financial performance
- 9.6.2.3 Product benchmarking
- 9.6.2.4 Strategic initiatives
- 9.6.3 Sanofi
- 9.6.3.1 Company overview
- 9.6.3.2 Financial performance
- 9.6.3.3 Product benchmarking
- 9.6.3.4 Strategic initiatives
- 9.6.4 Sun Pharmaceutical Industries Ltd.
- 9.6.4.1 Company overview
- 9.6.4.2 Financial performance
- 9.6.4.3 Product benchmarking
- 9.6.4.4 Strategic initiatives
- 9.6.5 Dr. Reddy's Laboratories Ltd.
- 9.6.5.1 Company Overview
- 9.6.5.2 Financial Performance
- 9.6.5.3 Product benchmarking
- 9.6.5.4 Strategic initiatives
- 9.6.6 Endo International plc
- 9.6.6.1 Company overview
- 9.6.6.2 Financial performance
- 9.6.6.3 Product benchmarking
- 9.6.6.4 Strategic initiatives
- 9.6.7 GlaxoSmithKline Plc
- 9.6.7.1 Company Overview
- 9.6.7.2 Financial Performance
- 9.6.7.3 Product Benchmarking
- 9.6.7.4 Strategic Initiatives
- 9.6.8 Wockhardt
- 9.6.8.1 Company overview
- 9.6.8.2 Financial Performance
- 9.6.8.3 Product benchmarking
- 9.6.8.4 Strategic initiatives
- 9.6.9 Viatris, Inc.
- 9.6.9.1 Company Overview
- 9.6.9.2 Financial Performance
- 9.6.9.3 Product Benchmarking
- 9.6.9.4 Strategic Initiatives
- 9.6.10 Apotex, Inc.
- 9.6.10.1 Company overview
- 9.6.10.2 Product benchmarking
- 9.6.10.3 Strategic initiatives
- 9.6.1 Teva Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-014-9
List of Tables
- Table 1 List of secondary sources
- Table 2 List of Abbreviation
- Table 3 Regulatory framework
- Table 4 Patent expiry of branded products
- Table 5 Healthcare expenses on pharmaceuticals
- Table 6 List of branded generic oral hormone products
- Table 7 List of generic anti-hypertensive products
- Table 8 Estimated new cancer case statistics 2020
- Table 9 Prevalence of GERD
- Table 10 List of topical branded generics
- Table 11 List of select oral branded generics from Cipla
- Table 12 Pharmacy density across major Europe countries
- Table 13 Europe branded generics market, company market share analysis, 2022
- Table 14 Key companies adopting expansion strategy
- Table 15 Key companies adopting acquisition strategy
- Table 16 Key companies adopting collaboration strategy
- Table 17 Key companies launching new products/services
- Table 18 Key companies adopting partnership strategy
- Table 19 Key Companies undergoing Other Strategies
- Table 20 Europe branded generics Market, by country, 2018 - 2030 (USD Million)
- Table 21 Europe branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 22 Europe branded generics Market, by application, 2018 - 2030 (USD Million)
- Table 23 Europe branded generics Market, by route of administration, 2018 - 2030 (USD Million)
- Table 24 Europe branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 25 Germany branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 26 Germany branded generics market, by application, 2018 - 2030 (USD Million)
- Table 27 Germany branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 28 Germany branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 29 UK branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 30 UK branded generics market, by application, 2018 - 2030 (USD Million)
- Table 31 UK branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 32 UK branded Generics Market, by distribution channel, 2018 - 2030 (USD Million)
- Table 33 France branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 34 France branded generics market, by application, 2018 - 2030 (USD Million)
- Table 35 France branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 36 France branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 37 Italy branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 38 Italy branded generics market, by application, 2018 - 2030 (USD Million)
- Table 39 Italy branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 40 Italy branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 41 Spain branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 42 Spain branded generics market, by application, 2018 - 2030 (USD Million)
- Table 43 Spain branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 44 Spain branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 45 Russia branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 46 Russia branded generics market, by application, 2018 - 2030 (USD Million)
- Table 47 Russia branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 48 Russia branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 49 Sweden branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 50 Sweden branded generics market, by application, 2018 - 2030 (USD Million)
- Table 51 Sweden branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 52 Sweden branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 53 Denmark branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 54 Denmark branded generics market, by application, 2018 - 2030 (USD Million)
- Table 55 Denmark branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 56 Denmark branded generics market, by distribution channel, 2018 - 2030 (USD Million)
- Table 57 Norway branded generics market, by drug class, 2018 - 2030 (USD Million)
- Table 58 Norway branded generics market, by application, 2018 - 2030 (USD Million)
- Table 59 Norway branded generics market, by route of administration, 2018 - 2030 (USD Million)
- Table 60 Norway branded generics market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Europe branded generics market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Commodity Flow Analysis
- Fig. 10 Market snapshot (2022) (USD Million)
- Fig. 11 Segment snapshot (2022) (USD Million)
- Fig. 12 Segment snapshot (2022) (USD Million)
- Fig. 13 Competitive snapshot
- Fig. 14 Penetration and growth prospect mapping
- Fig. 15 Europe branded generics market driver impact
- Fig. 16 Europe branded generics market restraint impact
- Fig. 17 SWOT analysis, by factor (Political & Legal, Economic, and Technological)
- Fig. 18 Porter's Five Forces Analysis
- Fig. 19 Europe branded generics market: Drug class outlook and key takeaways
- Fig. 20 Europe branded generics market: Drug class movement analysis
- Fig. 21 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 22 Antimetabolites market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 23 Hormones market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 24 Anti-hypertensive & lipid lowering drugs market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 25 Anti-depressants market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 26 Anti-psychotics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 27 Anti-epileptics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 29 Europe branded generics market: Application outlook and key takeaways
- Fig. 30 Europe branded generics market: Application movement analysis
- Fig. 31 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 32 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 33 Neurological and psychiatric diseases cases in Millions
- Fig. 34 Neurological diseases market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 35 Acute and chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 36 Gastrointestinal diseases market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 37 Dermatological diseases market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 39 Europe branded generics market: Route of administration outlook and key takeaways
- Fig. 40 Europe branded generics market: Route of administration movement analysis
- Fig. 41 Topical market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 42 Oral market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 43 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 45 Europe branded generics market: Distribution channel outlook and key takeaways
- Fig. 46 Europe branded generics Market: Distribution Channel Movement Analysis
- Fig. 47 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 48 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 49 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 50 Regional marketplace: Key takeaways
- Fig. 51 Europe: SWOT analysis
- Fig. 52 Europe branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 53 Germany country dynamics
- Fig. 54 GermanyTarget disease prevalence (Patient Volume) ('000), 2018 - 2030
- Fig. 55 Germany branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 56 UK country dynamics
- Fig. 57 Uk Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 58 UK branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 59 France Key country dynamics
- Fig. 60 France Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 61 France branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 62 Italy Key country dynamics
- Fig. 63 Italy Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 64 Italy branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 65 Spain Key country dynamics
- Fig. 66 Spain Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 67 Spain branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 68 Russia Key country dynamics
- Fig. 69 Russia Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 70 Russia branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 71 Denmark Key country dynamics
- Fig. 72 Denmark Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 73 Denmark branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 74 Sweden Key country dynamics
- Fig. 75 Sweden Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 76 Sweden branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 77 Norway Key country dynamics
- Fig. 78 Norway Target disease prevalence (Patient volume) ('000), 2018 - 2030
- Fig. 79 Norway branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 80 Rest of Europe branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 81 Heat map analysis
- Fig. 82 Strategic framework
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.